Moreover, lumican decreased the expression levels of the mesenchymal markers slug/snail-2 zeb1, vimentin and fibronectin and the epithelial marker E-cadherin in MDA-MB-231 breast cancer cells. This evidence concerns the gene FN1 and breast carcinoma.